"Trastuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
| Descriptor ID |
D000068878
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.875 D12.776.124.790.651.114.224.060.875 D12.776.377.715.548.114.224.200.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trastuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Trastuzumab [D12.776.124.486.485.114.224.060.875]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Trastuzumab [D12.776.124.790.651.114.224.060.875]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Trastuzumab [D12.776.377.715.548.114.224.200.875]
Below are MeSH descriptors whose meaning is more specific than "Trastuzumab".
This graph shows the total number of publications written about "Trastuzumab" by people in this website by year, and whether "Trastuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 7 | 7 |
| 2003 | 0 | 12 | 12 |
| 2004 | 0 | 17 | 17 |
| 2005 | 0 | 11 | 11 |
| 2006 | 0 | 12 | 12 |
| 2007 | 0 | 18 | 18 |
| 2008 | 0 | 10 | 10 |
| 2009 | 0 | 9 | 9 |
| 2010 | 1 | 16 | 17 |
| 2011 | 0 | 23 | 23 |
| 2012 | 0 | 19 | 19 |
| 2013 | 0 | 16 | 16 |
| 2014 | 1 | 15 | 16 |
| 2015 | 5 | 12 | 17 |
| 2016 | 4 | 6 | 10 |
| 2017 | 6 | 11 | 17 |
| 2018 | 7 | 8 | 15 |
| 2019 | 7 | 11 | 18 |
| 2020 | 4 | 11 | 15 |
| 2021 | 9 | 6 | 15 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 21 | 21 |
| 2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trastuzumab" by people in Profiles.
-
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clin Cancer Res. 2024 Apr 01; 30(7):1273-1280.
-
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr; 125:102720.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2024 01; 10:e2300285.
-
Correlation of HER2 Protein Level With mRNA Level Quantified by?RNAscope in Breast Cancer. Mod Pathol. 2024 Feb; 37(2):100408.
-
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nat Commun. 2023 11 03; 14(1):7053.
-
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398.
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 01; 42(1):47-58.
-
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024 Jan 20; 42(3):258-265.
-
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). J Nucl Med. 2023 11; 64(11):1690-1696.